Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Lyell Immunopharma ( (LYEL) ) just unveiled an announcement.
On June 17, 2025, Lyell Immunopharma announced new clinical data from its ongoing Phase 1/2 trial of LYL314, a CAR T-cell therapy for large B-cell lymphoma (LBCL). The trial showed promising results with high overall response rates and manageable safety profiles in both third- or later-line (3L+) and second-line (2L) settings. The company plans to initiate a randomized pivotal trial by early 2026 and has the manufacturing capacity to support clinical development and early commercial launch if approved.
The most recent analyst rating on (LYEL) stock is a Hold with a $80.00 price target. To see the full list of analyst forecasts on Lyell Immunopharma stock, see the LYEL Stock Forecast page.
Spark’s Take on LYEL Stock
According to Spark, TipRanks’ AI Analyst, LYEL is a Neutral.
Lyell Immunopharma’s stock is facing significant challenges primarily due to its financial performance, characterized by zero revenue and ongoing losses. Technical analysis shows neutral to slightly positive indicators, but valuation remains a concern due to negative earnings. The absence of earnings call data and corporate events limits additional insights into the company’s strategic direction.
To see Spark’s full report on LYEL stock, click here.
More about Lyell Immunopharma
Lyell Immunopharma, Inc. operates in the biotechnology industry, focusing on the development of innovative immunotherapies. The company specializes in creating chimeric antigen receptor (CAR) T-cell therapies, with a market focus on treating various types of lymphoma.
Average Trading Volume: 100,429
Technical Sentiment Signal: Sell
Current Market Cap: $150.6M
See more data about LYEL stock on TipRanks’ Stock Analysis page.